EyeBrain, a company developing medical devices for the early diagnosis of neurological diseases, announces today that its EyeBrain Tracker device is being used in a clinical trial exploring the dyskinesia induced by treating patients suffering from idiopathic Parkinson’s disease with levodopa.
The endpoint of the trial is to find biomarkers for the late-onset complications of a treatment regime using levodopa (BIODYS). This compound, which is naturally transformed into dopamine in the brain, is one of the only drugs available for slowing the effects of Parkinson’s disease. However, over time, it induces dyskinesia in these patients, which takes the form of abnormal movements primarily affecting the face (tongue, lips, jaw) and extending as far as the arms and legs.
Altogether, 30 people will be enrolled on the trial. Half of them will be Parkinson’s sufferers who have been treated with levodopa and have developed dyskinesia, while the other half will consist of healthy subjects who will be used as a control group.
The trial is being sponsored and financed by Bordeaux University Hospital and was set up by professor Jean-François Tison, a neurologist attached to the CNRS Physiopathology of Parkinsonian syndromes unit at the University of Bordeaux Two (the Institute of Neurodegenerative Diseases, CNRS UMR 5293E, Bezard). The EyeBrain Tracker device is being funded under the joint 2007-2013 State-Region Plan (Aquitaine Regional Council and the FEDER fund).
“Patients suffering from idiopathic Parkinson’s disease will undergo an acute test as part of a pre-operational assessment for stimulating the deep recesses of the brain,” explained professor Tison. The motricity effects of the treatment will be evaluated by measuring the speed of eye movements with the help of the EyeBrain Tracker.
“We will see whether levodopa modifies the parameters of blinking in a way that is correlated with the improvement in motricity,” said professor Tison. “Using the EyeBrain Tracker enables us to measure the motricity effect through eye movements, since the blinking parameters are also linked to the patient’s general motricity. The patient’s response to this trial is also a predictor of their reaction to the neurosurgery that will follow.”
The EyeBrain Tracker, which is already used in the early diagnosis of Parkinsonian syndromes, such as progressive supra-nuclear paralysis (PSP), cortico-basal degeneration (CBD) and multiple systems atrophy (MSA), is thus continuing to broaden its fields of application. It is now playing an important role in clinical research into other neurological diseases, such as multiple sclerosis, and is a valuable aid in the early diagnosis and follow-up of these diseases.
“We are delighted to know that the EyeBrain Tracker is playing a part in a clinical trial targeting idiopathic Parkinson’s,” said the chairman of EyeBrain, Serge Kinkingnéhun. “This forms part of our goal of making the benefits of eye motricity available to a larger number of people suffering from neurological pathologies.”
Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s. In western countries it affects 0.3 per cent of the general population. Its prevalence increases with age, reaching one per cent in the over-60s, and as much as four per cent in the over-80s. There are 100,000 sufferers in France and 8,000 new cases are diagnosed each year.About EyeBrain
The Mobile EyeBrain Tracker (EBT) comes as a complete solution including headphones, a computer with two screens and stimulation and analysis software. It is already being used routinely in hospitals to help with the early characterization of Parkinsonian syndromes. Studies are also underway for the diagnosis of multiple sclerosis (MS).
The Mobile EBT is the only device of its kind in the world to have obtained CE marking. The company has ISO 9001 and ISO 13485 certification.
EyeBrain, which is based in the Paris suburb of Ivry-sur-Seine, was founded in 2008 and currently employs 15 people. It has raised funding of EUR 1.2 million from the CapDecisif and G1J venture capital funds and already generates revenues through the sale of the EyeBrain Tracker. It is engaged in collaborations with the French National Health and Medical Research Institute (INSERM), the French National Scientific Research Center (CNRS), Paris University Hospitals group, the University of Paris-Descartes and the French Brain and Spinal Cord Institute.For further information about the company, go to: http://www.eye-brain.com
Lucie Nguyen | Andrew Lloyd & Associates
Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)
Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
21.06.2018 | Earth Sciences
21.06.2018 | Life Sciences
21.06.2018 | Earth Sciences